Medication & Safety
Does Insurance Cover Ozempic for Weight Loss? What to Know
Insurance coverage for Ozempic and Wegovy varies enormously by plan, indication, and country. Here is how to navigate co...
Ozempic's cost is one of the most significant barriers to treatment globally. Without insurance or government subsidy, the monthly cost in the United States approaches $1000 for the diabetes formulation and $1350 for Wegovy (semaglutide 2.4 mg). For most people in the world, this is simply unaffordable.
Understanding why the same molecule costs so dramatically differently depending on where you live — and what options exist within each context — is essential for informed treatment decisions.
Cost in the United States
Ozempic (semaglutide up to 2 mg): Approximately $850 to $1000 per month without insurance. The list price as of 2024 is $968 for a four-pen supply.
Wegovy (semaglutide 2.4 mg): Approximately $1300 to $1350 per month without insurance.
With insurance, patient responsibility varies enormously. Some diabetes plans cover Ozempic with a manageable copay. Wegovy (obesity indication) coverage is significantly less consistent — many insurers explicitly exclude weight loss medications.
Novo Nordisk offers a patient savings programme that can reduce monthly cost to as low as $25 per month for eligible commercially insured patients. For uninsured patients meeting income criteria, the NovoCare Patient Assistance Program may provide medication at reduced or no cost.
Cost in the United Kingdom
The National Health Service (NHS) in England approved Wegovy for weight management in 2023, but rollout is phased due to supply constraints. When prescribed on NHS: covered at standard prescription charge (~£9.90 per prescription as of 2024). Privately: approximately £150 to £250 per month depending on pharmacy and dose.
Cost in Canada
Health Canada approved Ozempic for type 2 diabetes. Wegovy approval arrived in Canada in 2023. Cost without coverage: approximately CAD $350 to $450 per month for Ozempic, higher for Wegovy. Coverage through provincial health plans is partial and varies significantly by province.
Cost in India and South Asia
Neither Ozempic nor Wegovy is manufactured or officially registered for weight loss indication in Pakistan or India as of mid-2025. Informally imported product from India-registered distributors carries authenticity and cold chain concerns.
Where available through private pharmacies in India as a prescribed product: approximately INR 10,000 to 15,000 per month (approximately $120 to $180 USD equivalent) — significantly lower than US pricing but still substantial in local income terms.
Pakistan: The Access Gap
In Pakistan, Ozempic and Wegovy are not DRAP-registered in the weight loss indication. Any available product is imported informally, with the associated risks of authenticity uncertainty, cold chain integrity questions, and no regulatory recourse if a product is substandard.
The practical monthly cost of informal import in Pakistan (including shipping, markup, and storage requirements) typically exceeds PKR 100,000 per month — prohibitive for virtually all patients.
This is the gap that METASLIM addresses: a DRAP-registered GLP-1 sublingual weight loss program with physician oversight, available nationwide through cash on delivery, at a cost accessible to Pakistani patients seeking GLP-1 pathway weight management.
Why Is Ozempic So Expensive?
The pricing reflects several factors:
Patent protection: Novo Nordisk holds patents on semaglutide that prevent generic production in most markets. These patents extend to the late 2030s in many jurisdictions.
Development costs: The STEP trial programme alone involved tens of thousands of participants over multiple years. Post-market safety surveillance adds to ongoing costs.
Market pricing strategy: In the US specifically, pharmaceutical pricing is set through negotiation with pharmacy benefit managers rather than regulated. Other countries negotiate national prices directly.
Supply constraints: Global demand for GLP-1 agonists has significantly exceeded supply during the rapid adoption period of 2023 to 2025, supporting premium pricing.
Manufacturing complexity: Semaglutide is a complex synthetic peptide requiring specialised large-scale production facilities.
Compounded Semaglutide as a Cost Alternative
During the US shortage period of 2023 to 2024, compounded semaglutide was available at $150 to $400 per month — a fraction of the branded cost. FDA has begun restricting compounded production as brand supply normalises. Safety concerns about compounded semaglutide are covered in a separate article.